San Antonio—Statins appear to provide significant protection against liver cancer and should be considered in patients at high risk for the disease, according to the investigator of the largest meta-analysis conducted to date on the question.
In 20 studies with approximately 2.6 million patients worldwide, use of the cholesterol agents was associated with a 43% reduction in the risk for hepatocellular carcinoma (HCC), said Muhammad T. Sarmini, MD, a gastroenterologist affiliated with the